ImmunityBio Advances Regulatory Discussions with FDA on Potential Resubmission Path for ANKTIVA® in BCG-Unresponsive Papillary Bladder Cancer

Core Viewpoint - ImmunityBio, Inc. has engaged in a Type B End-of-Phase meeting with the U.S. FDA regarding its supplemental Biologics License Application for ANKTIVA® in treating BCG-unresponsive non-muscle invasive bladder cancer [1] Group 1 - The meeting focused on the clinical status of ANKTIVA® (nogapendekin alfa inbakicept) combined with Bacillus Calmette-Guérin (BCG) [1]